Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Wall Street to open lower, eyes on Fed meeting

Published 09/16/2014, 09:03 AM
Updated 09/16/2014, 09:03 AM
© Reuters Traders work on the floor of the New York Stock Exchange (NYSE)

By Rodrigo Campos

NEW YORK (Reuters) - U.S. stocks were set to open lower on Tuesday with traders positioning for a Federal Reserve meeting expected to provide clues on the short term direction of U.S. interest rates.

Futures held on to slight losses after data showed U.S. producer prices were flat in August, pointing to muted inflation pressures that should see the Fed in no hurry to raise rates.

Later on Tuesday, the Fed will begin a two-day policy meeting. A statement and forecasts will be released Wednesday at 2:00 p.m. EDT followed by a press conference half an hour later.

"The big news comes (Wednesday) from the Fed and we'll work our way a bit lower before the announcement. Key points will likely suggest the Fed stays on hold until the middle of next year and that is already baked in," said Peter Cardillo, chief market economist at Rockwell Global Capital in New York.

"Markets are in a bit of a technical pullback," he said, adding the benchmark S&P 500 "will test 1,975 and probably could work toward 1,940-1,950, which I think would represent a buying opportunity."

S&P 500 e-mini futures were down 4 points and fair value - a formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract - indicated a lower open. Dow Jones industrial average e-mini futures <1YMc1> fell 31 points and Nasdaq 100 e-mini futures lost 11 points.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

U.S.-traded AstraZeneca (N:AZN) shares fell 1.6 percent in premarket trading after it signed a partnership deal with U.S. rival Eli Lilly (N:LLY) that could earn the British company up to $500 million if an experimental Alzheimer's drug proves successful.

(Editing by Bernadette Baum)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.